Skip to search formSkip to main contentSkip to account menu

GSK573719

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinuclidines

Narrower (1)

umeclidinium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Umeclidinium (GSK573719) dose response and dosing interval in COPD
Introduction: Dose differentiation is important in selecting COPD treatments. Objective: Characterize umeclidinium (UMEC), a long… 
2012
2012
Safety, Tolerability And Pharmacokinetics (PK) Of Single And Repeat Doses Of GSK573719 In Healthy Japanese Subjects
2012
2012
An Analysis of the Dose Response of Umeclidinium (GSK573719) Administered Once or Twice Daily in Patients With COPD
2012
2012
Evaluation Of The Effect Of Verapamil, An Inhibitor Of P-Glycoprotein And CYP3A4, On Systemic Exposure And Safety Profile Of GSK573719, A New Long-Acting Muscarinic Antagonist, And Vilanterol, An…
2011
2011
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing
Introduction: GSK573719 is a new, long-acting muscarinic antagonist offering sustained 24-h bronchodilation currently in phase… 
2011
2011
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
Introduction: GSK573719 is a new LAMA offering sustained 24-hour bronchodilation in development for the treatment of COPD… 
2011
2011
Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)